Resources

Respiratory syncytial virus (RSV) is a major, under–recognized public health problem causing more severe respiratory infections and hospitalizations in infants and young children each year than any other pathogen. New immunization tools have achieved licensure that could help change that.The opportunity to address this pervasive virus has never been better. To raise awareness, PATH and the World Health Organization are developing an evolving toolkit of communication materials that public health stakeholders and advocates can use to share information about RSV disease, new prevention tools, and delivery considerations. Other expert contributors include the US Centers for Disease Control and Prevention, Seattle Children's Hospital/University of Washington, UMC Utrecht, RRD Design, and more.To accommodate varying audience and engagement needs, this toolkit includes a stand-alone RSV primer presentation (and fact sheet) providing an overview of RSV disease and prevention options. Also available are modular PowerPoint slides that can be mixed and matched with the primer presentation to dive deeper into key topics for informing understanding and decision-making around RSV prevention. All slides come with speaker notes.To learn more about the toolkit, visit the web page.NOTE: Files available here as read-only. Editable files are readily available upon request. Please contact us.

Neonatal mortality is a critical challenge in underserved areas like Dharni, Maharashtra, where limited access to healthcare and tough terrain hinder timely medical intervention. To address this, PATH, in collaboration with AIIMS Nagpur, introduced a tele-SNCU hub-and-spoke model, leveraging telemedicine to provide real-time consultations and remote monitoring for newborns. This project brief highlights the implementation of this tele-SNCU model, which has significantly reduced neonatal deaths and referrals, enhancing care quality and contributing to progress toward SDG targets.

This is a simple, Excel-based tool for assessing and comparing costs of rotavirus vaccination programs with each rotavirus vaccine product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different rotavirus vaccines, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting a rotavirus vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages below. For questions or support, contact PATH's Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.

This is a simple, Excel-based tool for assessing and comparing costs of pneumococcal conjugate vaccine (PCV) vaccination programs with each PCV product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different PCVs, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting a PCV product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages below. For questions or support, contact PATH's Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.

Artemisinin-based combination therapy (ACT) is the primary malaria treatment in most malaria-endemic countries. To better understand the current ACT market and supply chain, PATH developed a market landscape with useful market information for stakeholders that purchase, procure, or use ACTs.The content of this landscape focuses on the current state of the ACT market—including supply, demand, market shares and prices, and active pharmaceutical ingredient and artemisinin suppliers.PATH hopes this landscape will be a valuable resource for partners, and we welcome any feedback or suggestions on the document.